Leukemia Clinical Trials in Boston

Showing 1021-1040 of 1,243 trials

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

NCT01173679

Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) are similar diseases of the white blood cells and are typically treated the same way. Recent research shows that a key enzyme in CLL cells is responsible for cell survival. This enzyme is called LYN kinase. Laboratory studies show that inhibition of LYN kinase in CLL cells results in the death of CLL cells. Dasatinib has the ability to inhibit LYN kinase and, therefore, should have some effect on CLL cells. The purpose of this study is to see of the study drug dasatinib, in combination with fludarabine and rituximab, is safe and effective to use for people with relapsed or refractory CLL/SLL.

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Massachusetts General Hospital10 participantsStarted Jul 2010

Boston, Massachusetts, United States • Boston, Massachusetts, United States • Boston, Massachusetts, United States

COMPLETEDPhase 2< 1 mile

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

NCT00622193

The purpose of this study is to evaluate doses of anamorelin for safety and efficacy in patients with non-small cell lung cancer.

Carcinoma, Non-Small-Cell Lung

Helsinn Therapeutics (U.S.), Inc228 participantsStarted Mar 2008

Little Rock, Arkansas, United States • Melbourne, Florida, United States • Augusta, Georgia, United States +30 more locations

Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

Leukemia Trials in Other Cities

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

Mouse Allergen and Asthma Intervention Trial

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Alisertib for Acute Myeloid Leukemia

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC

Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Perennial Allergic Rhinitis Study In Pediatric Subjects

Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer

Other Conditions in Boston